logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Leuprorelin acetate for advanced breast cancer in pre or perimenopausal women – adjuvant

< Back

Leuprorelin acetate for advanced breast cancer in pre or perimenopausal women – adjuvant

Drugs

Cancer and Palliative Care

October 2018


Leuprorelin acetate is being developed as an adjuvant treatment given by subcutaneous injection for pre and perimenopausal women with advanced breast cancer suitable for hormonal manipulation. Breast cancer is the most common female cancer in the UK. Breast cancers that are stimulated to grow by the hormones oestrogen or progesterone are known as hormone receptor-positive cancers. Advanced breast cancer is when the cancer has spread to other parts of the body. Treatments at this stage are not curative and will aim to reduce the progression of the cancer and metastases. Eligible patients may have surgery which is usually followed by adjuvant therapy (hormone or chemotherapy) to improve the success of the treatment.
Leuprorelin is a gonadotropin-releasing hormone (GnRH) analogue, when given chronically will block the production of oestrogen and progesterone hormones from the ovaries. A similar drug currently commonly used is goserelin, which is given as an injection every 4 weeks. If licensed, leuprorelin acetate will offer an additional adjuvant treatment option for pre and perimenopausal women with advanced breast cancer that is suitable for hormonal manipulation.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts